Vascular Dementia Clinical Trial Pipeline Expands as 11+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Merz Pharma, CSPC Ouyi Pharmaceutical, Resverlogix Corporation, Autifony Therapeutics

DelveInsight's "Vascular Dementia - Pipeline Insight, 2025" report provides comprehensive insights about 11+ companies developing 11+ pipeline drugs in the Vascular Dementia pipeline landscape. It covers the Vascular Dementia pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Vascular Dementia treatment landscape. Learn more about the evolving Vascular Dementia pipeline today @ https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Key Takeaways from the Vascular Dementia Pipeline Report

• In January 2026, A major JACC Seminar review confirmed that cognitive enhancers (donepezil, galantamine, memantine) only modestly improve cognition in VaD, particularly when co-occurring AD pathology is present
• In June 2025, researchers at UC San Diego identified a brain repair mechanism involving the CD39-A3AR signaling system, which was tested with piclidenoson (an A3AR-specific agonist currently in clinical trials for psoriasis), showing promise for treating vascular dementia by promoting brain tissue repair and recovery of memory and gait functions in preclinical models.
• In 2025, Resverlogix Corporation continued Phase II development of RVX-208 (Apabetalone), an epigenetic modulator targeting BET proteins, for cognitive enhancement in vascular dementia patients.
• DelveInsight's Vascular Dementia Pipeline Insight report depicts a robust space with 11+ active players working to develop 11+ pipeline therapies for Vascular Dementia treatment.
• The leading Vascular Dementia companies include Merz Pharma, CSPC Ouyi Pharmaceutical, Resverlogix Corporation, Autifony Therapeutics, Beijing Joekai Biotechnology, Neuraltus Pharmaceuticals, and others developing innovative therapeutic approaches.
• Promising Vascular Dementia therapies include Butylphthalide soft capsule, Galantamine, Fufangdanshen Tablets, Donepezil hydrochloride (Aricept), Rivastigmine, Prospekta, Cerebrolysin, RVX-208, and others targeting novel mechanisms to address cognitive impairment and neurodegeneration.

Download for updates and the latest revolution in Vascular Dementia care @ https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Vascular Dementia Emerging Drugs Profile

• Butylphthalide soft capsule: CSPC Ouyi Pharmaceutical

Butylphthalide (DL-3-n-butylphthalide) is a synthetic compound originally extracted from the seeds of Apium graveolens (Chinese celery). This innovative therapeutic agent exerts multiple neuroprotective mechanisms including antioxidation, anti-inflammation, and enhancement of neuroplasticity. The drug works by improving the oxidative stress response of the nervous system, inhibiting neuronal apoptosis and autophagy, regulating the function of the central cholinergic system, and promoting neuroplasticity. The compound has shown significant potential in ameliorating cognitive decline associated with vascular brain injury. By targeting multiple pathological pathways simultaneously, butylphthalide offers a comprehensive approach to treating vascular cognitive impairment. The drug is currently being evaluated in Phase III clinical trials for the treatment of Vascular Dementia in China.

• RVX-208 (Apabetalone): Resverlogix Corporation

RVX-208, also known as Apabetalone, is a first-in-class small molecule that selectively targets the bromodomain and extra-terminal (BET) family of epigenetic readers, specifically bromodomain-containing protein 4 (BRD4). This novel epigenetic modulator works by modulating gene expression involved in inflammation, lipid metabolism, and vascular function. In vascular dementia, the drug addresses multiple pathological mechanisms including chronic inflammation, endothelial dysfunction, and atherosclerosis progression. RVX-208's ability to target the epigenetic regulation of vascular and inflammatory pathways positions it as a promising candidate for addressing the complex pathophysiology of vascular dementia. The drug is currently being evaluated in Phase II clinical trials for the treatment of Vascular Dementia.

• Galantamine: Merz Pharma

Galantamine is a selective, reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric modulator of nicotinic acetylcholine receptors. This dual mechanism of action enhances cholinergic neurotransmission in the central nervous system. The drug works by inhibiting the breakdown of acetylcholine, thereby increasing its availability in synaptic clefts, and by potentiating the action of acetylcholine at nicotinic receptors. In vascular dementia, cholinergic deficit contributes significantly to cognitive impairment, and galantamine addresses this by enhancing cholinergic function. Galantamine has demonstrated efficacy in improving cognitive function, activities of daily living, and behavioral symptoms in dementia patients. The drug's well-established safety profile and dual mechanism make it a valuable therapeutic option for managing cognitive symptoms in vascular dementia. The drug is currently being evaluated for the treatment of Vascular Dementia and has shown promise in clinical studies.

• Fufangdanshen Tablets: Traditional Chinese Medicine

Fufangdanshen Tablets represent a complex traditional Chinese medicine formulation containing multiple bioactive compounds from herbs including Salvia miltiorrhiza (Danshen), Panax notoginseng (Sanqi), and Borneol. The primary active components include tanshinone and salvianolic acid from Danshen, which exert potent antioxidant and anti-inflammatory effects. Tanshinone inhibits inducible nitric oxide synthase (iNOS) and matrix metalloproteinase 2 (MMP-2), reduces free radical formation, and protects against oxidative damage. Salvianolic acid demonstrates strong antioxidant properties and inhibits inflammatory cascades involved in neurodegeneration. Borneol, another key component, enhances blood-brain barrier permeability, facilitating the delivery of therapeutic compounds to the central nervous system. In vascular dementia, this multi-component formulation targets multiple pathological processes including oxidative stress, inflammation, impaired cerebral blood flow, and neuronal damage. The synergistic action of these compounds offers comprehensive neuroprotection and potential cognitive enhancement. The drug has completed Phase II clinical trials demonstrating improvements in cognitive function and cerebral blood flow in vascular dementia patients.

For more information on the Vascular Dementia Emerging Drugs Profile, visit https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Vascular Dementia Pipeline Report Provides

• Detailed insights about companies developing therapies for Vascular Dementia, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Vascular Dementia treatment.
• Vascular Dementia companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Vascular Dementia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Vascular Dementia market.

Learn more about Vascular Dementia Drugs opportunities in our comprehensive Vascular Dementia pipeline report @ https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Vascular Dementia Companies

There are 11+ key companies, such as Merz Pharma, CSPC Ouyi Pharmaceutical, Resverlogix Corporation, Autifony Therapeutics, Beijing Joekai Biotechnology, Neuraltus Pharmaceuticals, and others, developing therapies for Vascular Dementia, with CSPC Ouyi Pharmaceutical having its Vascular Dementia drug candidate in the most advanced Phase III stage.

DelveInsight's Vascular Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Vascular Dementia products have been categorized under various Molecule types such as:

• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Vascular Dementia treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/vascular-dementia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Vascular Dementia Pipeline Report

• Coverage: Global
• Vascular Dementia companies: Merz Pharma, CSPC Ouyi Pharmaceutical, Resverlogix Corporation, Autifony Therapeutics, Beijing Joekai Biotechnology, Neuraltus Pharmaceuticals, and others
• Vascular Dementia Therapies: Butylphthalide soft capsule, Galantamine, Fufangdanshen Tablets, Donepezil hydrochloride (Aricept), Rivastigmine, Prospekta, Cerebrolysin, RVX-208, and others
• Vascular Dementia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Vascular Dementia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.